title: [Etoposide combination chemotherapy for malignant lymphoma: a report of 91 cases].
abstract: From August 1984 to August 1994 ninety-one caese of malignant lymphoma (NHL 84 casese, HD 7 cases) were treated with Etoposide (VP-16) combinationn chemotherapy. In 70 evaluable patients, 18 achieved CR, 35 PR, total response rate was 75.7%, response time (RT) 1-79 months, medium response time (MRT) 9 months, survival time (ST) 2-79 months, medium survival time (MST) 12 months. The therapeutic efficacy was better than VP-16 alone. The major side effects were myelosuppression and gastrointestinal toxicity. In COPEP, CHEP, PEP and IEP regimens, best result was seen in COPEP (CTX + VCR + PYM + VP-16 + PDN), with a response rate of 93%. Authors suggest that COPEP protocol could be the first line treatment for patients with malignant lymphoma who did not tolerate anthracycline drugs and the second line treatment for anthracycline-resistant patients.
authors.affiliation: Cancer Institute Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing.
authors.forename: F
authors.initials: F
authors.lastname: Feng
authors.forename: L
authors.initials: L
authors.lastname: Zhou
authors.forename: X
authors.initials: X
authors.lastname: He
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001761:Bleomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011241:Prednisone